Introduction {#S1}
============

Leukemic relapse is the single biggest cause of treatment failure after hematopoietic stem cell transplant (SCT) for hematological malignancies, and its management remains largely unsuccessful.^[@R1]^ Patients relapsing with acute leukemia within 6 months of SCT have a one year survival of less than 20%.^[@R2],\ [@R3]^ In comparison, later relapse of acute leukemia after SCT carries a better prognosis, but is still plagued by a high mortality from progressive disease.^[@R4]^ Consequently, no standard approach exists for management of relapsed disease after SCT. Typically most patients will receive chemotherapy and/or a donor lymphocyte infusion, while others may only be offered palliative treatment.^[@R5]--[@R8]^ Selected patients with a good performance status, in whom some disease control is achieved, may receive a second SCT. However, a second SCT is not without risk. Offering a second opportunity for cure logically requires either intensification of the conditioning regimen or enhancement of the graft-versus-leukemia (GVL) effect, which can be achieved by selecting an alternative donor or by promoting a more rapid and complete immune reconstitution.^[@R1],\ [@R9]^

At our institution we offered a second SCT to selected patients deemed fit enough and with sufficient disease control to survive the procedure without early death from disease progression or treatment related mortality. In the setting of myeloablative T cell depleted SCT we sought to augment the GVL effect with a T cell-replete second transplant and reduced immune suppression. Here we describe our single institute experience of T cell-replete, reduced intensity, second allogeneic SCT from the original donor in 25 patients drawn from a cohort of 59 patients who relapsed after a matched sibling T cell depleted SCT.

Patients, materials, and methods {#S2}
================================

Patients {#S3}
--------

Between 1997 and 2011, 220 consecutive patients with a hematological malignancy underwent a myeloablative T cell depleted (TCD) SCT from an HLA-identical sibling on National Heart, Lung and Blood Institute (NHLBI) institutional review board--approved protocols. Patients and donors provided written informed consent before enrolling in the transplantation protocols.

First Transplant {#S4}
----------------

All patients received a TCD granulocyte colony-stimulating factor (G-CSF) -- mobilized peripheral blood stem cell transplant. G-CSF was administered to all donors at a targeted dose of 10--12 μg/kg of body weight subcutaneously for 5 consecutive days prior to collection. The conditioning regimen consisted of 1200 or 1360 cGy total body irradiation (TBI), cyclophosphamide (Cy, 120 mg/kg over 2 days), with or without fludarabine (Flu, 125mg/m^2^ over 5 days). Depletion of T cells from the stem cell transplant products was accomplished by selection of CD34+ cells using either the CellPro system (CellPro Inc., Bothel, WA), Isolex system (Nexell Therapeutics Inc, Irvine, CA), or the Miltenyi CliniMacs system (MiltenyiBiotec Inc., Auburn, CA). On the day of SCT all patients received this enriched CD34+ stem cell product with a target dose of 5 × 10^6^ CD34+ cells/kg, accompanied by a predetermined, protocol-specific dose of 0.2 -- 1 × 10^5^ T cells/kg that was obtained by supplementing the final product with T cells from the original unmanipulated peripheral blood stem cell component. All patients received low-dose cyclosporine A (CSA) (target plasma level, 100--200 mcg/L), starting on day −4 per protocol. In the absence of significant acute GVHD (grade \> 1), a donor lymphocytes infusion (DLI, 1× 10^7^ CD3+ cells/kg) was administered between days 45 to 100 after transplantation. Standard prophylaxis against infection included fluconazole and trimethoprim/sulfamethoxazole, which were administered for at least 6 months after transplantation, and weekly surveillance was performed for cytomegalovirus (CMV) antigenemia as described previously.^[@R10],\ [@R11]^

Second Transplant {#S5}
-----------------

Second transplant regimens are detailed in [Table 2](#T3){ref-type="table"}. GVHD prophylaxis consisted of cyclosporine alone (target plasma level, 100--200 mcg/L). Standard prophylaxis against infection and virus surveillance are the same as for the first transplant.

Definition of Clinical Terms {#S6}
----------------------------

Overall survival (OS) was calculated from the interval between the date of transplantation and death, or last follow-up visit. Relapsed disease for acute leukemia, myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) was defined by morphologic or cytogenetic evidence, either in peripheral blood or in bone marrow.

Statistical analysis {#S7}
--------------------

Survival analysis for time-to-event data was used to analyze the effects of baseline risk factors relapse and overall survival. For relapse, patient who did not relapse before death or by the end of the study were treated as censored. For overall survival, patients who were alive by the end of the study were treated as censored. Survival was measured from time of relapse after the first SCT to the last contact date or death. Effects of the baseline risk factors relapse and overall survival were evaluated using the univariate Cox proportional hazard models. Kruskal-Wallis test was used for the treatment of non-transplanted patients. The overall effects of the risk factors were evaluated using the Log-rank p-values, and effects of the individual risk factors were evaluated using p-values based on the two-sided t-tests with 0.05 significance level. Statistical analyses were performed with SPSS 15.0 (IBM SPSS, New York) and Prism 5 (GraphPad Software, San Diego, CA) software.

Results {#S8}
=======

Patient Characteristics {#S9}
-----------------------

General patient characteristics after first SCT are shown in [table 1a](#T1){ref-type="table"} and [1b](#T2){ref-type="table"}. Fifty-nine patients relapsed with cytogenetic or morphological evidence of disease recurrence after their first SCT. Relapses occurred in 31 AML/MDS, 17 ALL, 4 B cell malignancies (2 CLL, 1 NHL, 1 MM), 6 CML blast phase and 1 CML accelerated phase (Molecular relapses in CML patients were not included in this study, and no chronic phase CML patient had a hematological relapse). The median age at time of first SCT for the 30 males and 29 females that relapsed was 36 (range 9 -- 66) years. Thirty-eight patients relapsed within 6 months (early relapse) at a median of 85 days and 21 patients relapsed after 6 months (late relapse) at a median of 465 days after their first transplant. Patient characteristics of SCT recipients vs other treatments did not show significant differences in gender, age, disease status and risk classification at first SCT, Karnofsky performance status, days of relapse post first SCT in both early and relapse groups. All of our patients were from other institutions or overseas. As a result, cytogenetics were not always available limiting a full description of the kinetics of the disease and chemorefractoriness.

Second Transplant Characteristics {#S10}
---------------------------------

Characteristics of second transplant procedures are shown in [table 2](#T3){ref-type="table"}. A second T-replete SCT from the original donor using a reduced-intensity conditioning regimen was performed in 25 patients: 13/38 early relapses and 12/21 late relapses. The median number of CD34+ cells infused was 5.76 × 10^6^ cells/kg. Nineteen of 25 patients received myeloablative conditioning (MAC) with either Busulphan or Melphalan, and 6 received a non-MAC specific to their disease. There was no statistically significant difference in survival outcome in patients who received MAC or non-MAC SCT (median 211 vs 195 days, p=0.36) (see [figure 3](#F3){ref-type="fig"}).

Prior to second transplant, 1 patient relapsing early and 3 patients relapsing late achieved complete remission (2 CR and 1 CRi) after chemotherapy alone or in combination with DLI. However, no survival benefit of obtaining a remission prior to the second HSCT was noted (p=0.55, data not shown).

Non transplant treatment {#S11}
------------------------

The treatment for patients not receiving a second SCT is summarized in [table 3](#T4){ref-type="table"}. Of these 34 patients (25 early and 9 late relapse), 9 received chemotherapy with intent to obtain remission in combination with DLI, 6 received chemotherapy alone, 10 received DLI alone, and 9 received palliative chemotherapy or hospice care only. In early relapsed patients DLI were given more frequently than those given a second SCT (p=0.02). Otherwise, there were no differences regarding treatment options between patients that received or did not received a second transplant in either early or late relapse groups. Amongst non-transplant recipients no treatment emerged as superior for overall survival (p=0.19).

Relapse and Overall Survival {#S12}
----------------------------

The distribution of hematological disease type and overall survival for patients relapsing after the first SCT is shown in [figure 1](#F1){ref-type="fig"}. The overall survival for early versus late relapse after SCT is shown in [figure 2](#F2){ref-type="fig"}. Patients experiencing an early relapse included AML/MDS (50%), ALL (32%), CML blast phase (13%), and B cell malignancies (NHL and MM 5%). Patients experiencing a late relapse included AML/MDS (57%), ALL (24%), CML blast or accelerated phase (9%), and B cell malignancies (CLL 10%). Patients relapsing late had a longer overall survival compared with patients relapsing early (p=0.0002). No patient relapsing early after the first SCT survived beyond 1 year following relapse, while the probability of one year survival for patients with a late relapse was 33% (HR=2.97, 95% CI 1.683--5.241 p=0.0002). At 3 years after relapse, the actuarial survival was 0 for early relapsed patients (with or without a second SCT). In contrast, the Kaplan-Meier estimate of actuarial survival for late relapsed patients was 17% after second SCT and 0% without. However, a second SCT in early relapse did not significantly prolong survival when compared with patients receiving other treatments (median 109 vs 80 days, HR = 1.308, 95% CI 0.69--2.17, p = 0.41). Similarly a second SCT for late relapse only modestly prolonged survival (median survival 363.5 vs 162 days, HR = 1.44, 95% CI 0.52 -- 4.0, p = 0.49). Among 21 patients relapsing late not receiving SCT, 1 patient with CLL, was a long term survivor at a median follow-up of 6.3 years while 2 of 12 transplanted patients (with AML and MDS RAEB2) were long-term survivors beyond 5 years.

In 13 early relapsed patients receiving second HSCT the cause of treatment failure was relapse in all but two patients (1 death from grade IV gastrointestinal GVHD and 1 from severe hepatic veno-occlusive disease). Four of the 13 patients developed acute GVHD, and no survival benefit was noted from acute GVHD in these patients (p=0.5041, see [supplementary figure](#SD1){ref-type="supplementary-material"}). In contrast, in the 12 patients relapsing late after SCT there was a 58% probability of dying from relapse and a 25% probability of non-relapse mortality (organ failure and infection, [Table 2](#T3){ref-type="table"}). In this group, 4 out of the 12 patients developed acute GVHD after second HSCT. However, again no survival benefit was noted in patients with acute GVHD (p=0.5841, see [supplementary figure](#SD1){ref-type="supplementary-material"}). There was no observed chronic GVHD in all patients received second SCT.

Discussion {#S13}
==========

Relapse of a hematological malignancy after an SCT given with intent to cure the disease represents a devastating treatment failure with no ideal treatment options. While there is some consensus that chemotherapy associated with a donor lymphocyte infusion can prolong survival, only a small minority of patients become long term survivors.^[@R12],\ [@R13]^ A second SCT may bring a second chance of cure if the second transplant strategy provides a more intensive antileukemic conditioning regimen or a stronger GVL effect.^[@R9]^ Nevertheless, second SCT carries a high risk of treatment failure, both from relapse and non-relapse mortality.^[@R14]^ Because patients relapsing after SCT show diversity in the aggressiveness and chemosensitivity of their disease, and vary widely in their performance status, second transplants tend to be offered on an individual basis to selected patients, usually those with better disease control and good performance status. An additional factor determining treatment for relapse is dictated by patient preference for either further intensive treatment or palliative measures, and the availability of donor. As a consequence there are no prospective randomized studies comparing transplant and non-transplant treatments for hematological malignancy relapsing after SCT.

We review here our approach to treatment of relapse after allogeneic SCT in selected patients with at least partial control of their disease who could tolerate a second SCT. Because of the better outcomes described for late relapse disease,^[@R2],\ [@R4]^ a greater proportion of second transplants were performed in patients relapsing after six months of their first SCT (57% vs 34%). The second SCT was performed with a T cell-replete transplant using only cyclosporine as GVHD prophylaxis in order to enhance the GVL effect over the original T cell depleted transplant. In this way it was hoped that a second transplant from the same donor could prolong survival and achieve a second chance of cure of malignancy. While presenting data for relapsed patients not receiving SCT, it must be pointed out that the groups are not matched - there was an inevitable bias in selecting patients for second SCT based on their general fitness, degree of disease control after relapse treatment, patient's choice to undergo further intensive treatment, and the availability of donor. Nevertheless, despite more favorable features of the second transplant group, it was disappointing that such patients did not experience an important prolongation of survival with the procedure. This disappointing outcome was shared among all patients regardless of the ability to successfully obtain a complete remission prior to a second SCT. Patients relapsing early after their first SCT had at best a 3 months survival advantage with a second SCT, offset by inevitably prolonged hospitalization. Comparable to other experience, patients relapsing late after their first SCT generally had a more favorable outcome.^[@R2],\ [@R15]^ The one year probability of survival reached 33% for late relapsed patients undergoing second SCT. Overall there was 17% survival for late relapsed patients given a second SCT maintained over the 6 years of follow-up in our study.

This is the first study to our knowledge of patients receiving a T cell-replete transplant for disease relapsing after an initial T cell depleted SCT. However, our study is limited by the sample size, selection bias for second transplantation, and availability of donors for SCT or DLI.

In conclusion these results indicate that the additional GVL effect from the unmanipulated second SCT was not sufficient to control relapsed disease in most patients who originally received a T cell-depleted SCT. A meaningful survival benefit from second SCT was only observed in late relapsed patients, and may have been due to selection bias. Based on this 14 year observation we no longer offer second SCT for patients relapsing within 6 months of transplant, and plan only to further study second SCT for late relapsed patients in the context of randomized trials comparing SCT with other treatments. It should be noted, however, that these findings specifically relate to the myeloablative regimens used in this patient group. Better outcomes after relapse might be observed in patients who received reduced intensity conditioning for the first SCT and more intensive conditioning for the second SCT. Consistent with this observation, recent studies have demonstrated that simply repeating the first SCT maneuver in treating patients with relapsed ALL provides minimal benefit, and that intensifying the conditioning or selecting an alternative donor may confer a greater antileukemic effect.^[@R16]^

Strategies that include a combination of therapeutic modalities to promote GVL while minimizing risks of toxicity and GVHD may improve outcomes for patients with relapsed disease after SCT. Recent studies have demonstrated the efficacy of azacitidine in the treatment of relapsed AML. Azacitidine up-regulates the expression of epigenetically silenced tumor antigens to promote cytotoxic CD8+ T cell responses and augment the GVL effect. Complete remission rates of 20% -- 40% have been noted when used as a single agent to treat patients with AML that have relapsed after SCT. Azacitidine also appears well tolerated, and is associated with an expansion of regulatory T cells and low rates of GVHD when used early after SCT.^[@R17]^ Recently, the combination of azacitidine and DLI as first salvage therapy for relapsed AML or MDS after SCT has been explored and appears safe with low rates of acute GVHD (grades III--IV of 10%). An overall response rate of 30% was observed, with 17% durable complete remissions (median duration, 777 days), demonstrating the feasibility of combining azacitidine with cellular therapies to augment anti-leukemic responses while minimizing toxicity.^[@R18]^ In this context, the combination of epigenetic modifying agents, such as azacitidine, lenalidomide and histone deacetylase inhibitors, with novel cellular therapy to include prophylactic DLIs, natural killer cell infusions, and leukemia-specific T cells or leukemia vaccines provides an exciting new avenue of research that may lead to improved treatment of leukemia relapse after allogeneic SCT.^[@R19],\ [@R20]^
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###### 

Characteristics of relapsed patients after first SCT: Early Relapse \< 180 days

                                                 No 2^nd^ SCT   Received 2^nd^ SCT   P
  ---------------------------------------------- -------------- -------------------- ------
  Number                                         25             13                   
  Gender (M/F)                                   12/13          8/5                  NS
  Age median/range (year)                        33 (14--55)    35 (16--60)          NS
  Disease status at 1^st^ SCT                                                        NS
  AML CR1                                        \-             3                    
   CR2                                           3              2                    
   \>CR2/MDS                                     8              3                    
   CML BC                                        5              \-                   
  ALL CR2/3                                      4              1                    
   Relapse                                       3              4                    
  Other (MM NHL)                                 2              \-                   
  Risk classification                                                                NS
  High risk                                      18 (72%)       7 (54%)              
  Standard and Intermediate                      7 (28%)        6 (46%)              
  Karnofsky % median (range)                     90 (20--90)    90 (50--90)          NS
  Day of relapse post 1^st^ SCT median (range)   91 (0--170)    80 (0--133)          NS
  Treatment (excluding SCT)                                                          
    DLI                                          16             3                    0.02
    Chemo -- remission intent                    10             7                    NS
    Palliative or None                           6              5                    NS

Abbreviations: SCT = stem cell transplantation; CML BC = CML in blast phase; DLI = donor lymphocyte infusion; NS = not statistically significant

###### 

Characteristics of relapse patients after second SCT: Late Relapse ≥ 180 days

                                                 No 2^nd^ SCT      Received 2^nd^ SCT   P
  ---------------------------------------------- ----------------- -------------------- ----
  Number                                         9                 12                   
  Gender (M/F)                                   3/6               7/5                  NS
  Age median/range (year)                        37 (9--44)        36 (13--66)          NS
  Disease status at 1^st^ SCT                                                           NS
  AML CR1                                        1                 3                    
   CR2                                           1                 \-                   
   \>CR2/MDS                                     1                 6                    
  CML AP                                         1                 \-                   
   BC                                            \-                1                    
  ALL CR1                                        1                 \-                   
   CR2/3                                         3                 1                    
  CLL                                            1                 1                    
  Risk classification                                                                   NS
  High risk                                      2 (22%)           7 (58%)              
  Standard and Intermediate                      7 (78%)           5 (42%)              
  Karnofsky % median (range)                     90 (50--90)       90 (50--90)          NS
  Day of relapse post 1^st^ SCT median (range)   254 (181--3678)   598 (220--5091)      NS
  Treatment (excluding SCT)                                                             
    DLI                                          3                 5                    NS
    Chemo -- remission intent                    5                 5                    NS
    Palliative or None                           3                 5                    NS

Abbreviations: SCT = stem cell transplantation; CML AP = CML in accelerated phase; CML BC = CML in blast phase; DLI = donor lymphocyte infusion; NS = not statistically significant

###### 

Profile of second transplanted patients

  Sex                 Age   Diagnosis at 1st SCT   Cytogenetics at diagnosis   Day of relapse   DLI   Chemo pre 2nd SCT   Disease status prior to 2nd SCT   Conditioning for 2nd SCT   Outcome        Survival Days Post relapse
  ------------------- ----- ---------------------- --------------------------- ---------------- ----- ------------------- --------------------------------- -------------------------- -------------- ----------------------------
  **Early relapse**                                                                                                                                                                                   
  M                   25    AML CR1                Complex                     133              \+    FLAG-I              NR                                Bu                         VOD            41
  F                   31    AML CR1                +8, t(5;9)                  91               \+    FLAG-I              NR                                Flu/Bu                     Relapse        211
  F                   27    ALL Relapse            UA                          77               −     V+P                 NR                                BC/VP/Cy                   Relapse        216
  M                   20    ALL Relapse            complex                     84               −     \-                  NR                                Mel/VP                     Relapse        96
  F                   36    AML/MDS NR             UA                          65               −     \-                  NR                                Flu/Mel                    Relapse        337
  F                   48    ALL CR3                UA                          92               −     HyperCVAD           NR                                Bu                         Relapse        71
  M                   36    AML CR2                UA                          57               −     \-                  NR                                FLAG                       Relapse        182
  F                   49    AML/MDS NR             Complex                     80               \+    \-                  NR                                FLAG-I                     Relapse        208
  F                   16    AML CR1                +8, t(11;19)                85               −     \-                  NR                                FLAG                       Relapse        159
  F                   36    AML CR2                t(9:22), inv3               56               −     \-                  NR                                Flu/Bu                     Relapse        65
  M                   60    AML/MDS NR             UA                          78               −     Flu                 NR                                Bu                         Relapse        94
  F                   35    ALL Relapse            normal                      99               −     HyperCVAD           CR                                Mel                        GVHD           109
  M                   24    ALL Relaplse           UA                          NR               −     VAD                 NR                                Flu/VP/Mel                 Relapse        67
  **Late relapse**                                                                                                                                                                                    
  M                   66    AML CR1                complex                     220              −     \-                  NR                                Flu/Bu                     Alive          \>921
  F                   21    AML/MDS CRi            +8, +14p                    270              −     \-                  NR                                Flu/TBI                    MOF            73
  F                   38    AML CR1                normal                      1120             \+    \-                  NR                                FLAG-I                     Relapse        367
  M                   13    AML/MDS NR             −7                          1149             −     \-                  NR                                Flu/Bu                     Alive          1378
  F                   44    CML BC                 Complex                     1346             \+    \-                  NR                                FLAG-IM                    Relapse        219
  F                   40    AML/MDS NR             UA                          1788             −     \-                  NR                                Flu/Mel                    Relapse        360
  M                   31    AML Relapse            T(8;21)                     303              \+    FLAG-I              NR                                Flu/Bu                     Relapse        298
  M                   38    AML/MDS NR             −7, +8                      363              −     IA                  CRi                               Flu/Bu                     Relapse        591
  M                   25    ALL CR2                Normal                      374              −     FLAG-I              CR                                Flu/Bu                     Pulm Failure   681
  M                   17    AML CR1                normal                      465              −     \-                  NR                                FLAG-I                     RSV            28
  M                   37    CLL RAI stage 4        −17p, −13q                  731              \+    Ritux + other       NR                                Flu/Bu                     Relapse        190
  F                   35    AML/MDS NR             complex                     5091             \+    FLAG-I              CR                                Flu/Bu                     Relapse        703

Abbreviations: UA = unavailable; FLAG-IM = fludarabine, cytarabine, G-CSF, idarubicin, gemtuzumab; V+P = vincristine + prednisone; HyperCVAD = cyclophosphamide, vincristine, adriamycin, dexamethasone; Flu = fludarabine; VAD = vincristine, doxorubicin, dexamethasone; IA = idarubicin; Ritux = rituximab; Bu = busulfan; Mel = melphalan; VP = etopside; TBI = total body irradiation; VOD = hepatic veno-occlusive disease; MOF = multiple organ failure; Pulm = pulmonary; RSV = respiratory syncytial virus infection

###### 

Treatment of non-second transplanted patients

                                                     Number   Survival post relapse (days median range)   P
  -------------------------------------------------- -------- ------------------------------------------- ------
   **Early relapse**                                                                                      0.19
  Therapy with intent to obtain remission with DLI   7        93 (35--941)                                
  Therapy with intent to obtain remission no DLI     3        107 (75--149)                               
  DLI alone                                          9        130 (11--333)                               
  Palliative (to support blood counts) or none       6        38 (3--110)                                 
   **Late relapse**                                                                                       
  Therapy with intent to obtain remission with DLI   2        473 (165, 781)                              
  Therapy with intent to obtain remission no DLI     3        64 (34--1799)                               
  DLI alone                                          1        346                                         
  Palliative (to support blood counts) or none       3        64 (34--192)                                

Abbreviations: DLI = donor lymphocyte infusion
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